Corcept therapeutics incorporated CORT.US Overview
CORT AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
CORT Current Performance
-1.87%
Corcept therapeutics incorporated
-1.83%
Avg of Sector
-0.40%
S&P500
CORT Key Information
CORT Revenue by Segments
Browsing restrictions can be lifted for a fee.
CORT Net Income
Browsing restrictions can be lifted for a fee.
CORT Cash Flow
Browsing restrictions can be lifted for a fee.
CORT Profit Margin
Browsing restrictions can be lifted for a fee.
CORT PE Ratio River
Browsing restrictions can be lifted for a fee.
CORT Financial Forecast
Browsing restrictions can be lifted for a fee.
CORT Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
CORT Profile
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Price of CORT
CORT FAQ
When is CORT's latest earnings report released?
The most recent financial report for Corcept therapeutics incorporated (CORT) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CORT's short-term business performance and financial health. For the latest updates on CORT's earnings releases, visit this page regularly.
Where does CORT fall in the P/E River chart?
According to historical valuation range analysis, Corcept therapeutics incorporated (CORT)'s current price-to-earnings (P/E) ratio is 59.18, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of CORT?
According to the latest financial report, Corcept therapeutics incorporated (CORT) reported an Operating Profit of 3.42M with an Operating Margin of 2.17% this period, representing a decline of 88.42% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is CORT's revenue growth?
In the latest financial report, Corcept therapeutics incorporated (CORT) announced revenue of 157.21M, with a Year-Over-Year growth rate of 7.09%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does CORT have?
As of the end of the reporting period, Corcept therapeutics incorporated (CORT) had total debt of 6.84M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does CORT have?
At the end of the period, Corcept therapeutics incorporated (CORT) held Total Cash and Cash Equivalents of 89.82M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does CORT go with three margins increasing?
In the latest report, Corcept therapeutics incorporated (CORT) achieved the “three margins increasing” benchmark, with a gross margin of 98.5%%, operating margin of 2.17%%, and net margin of 12.9%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CORT's profit trajectory and future growth potential.
Is CORT's EPS continuing to grow?
According to the past four quarterly reports, Corcept therapeutics incorporated (CORT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.19. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of CORT?
Corcept therapeutics incorporated (CORT)'s Free Cash Flow (FCF) for the period is 5.02M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 78.85% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of CORT?
The latest valuation data shows Corcept therapeutics incorporated (CORT) has a Price-To-Earnings (PE) ratio of 59.18 and a Price/Earnings-To-Growth (PEG) ratio of -4.25. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.